Back to News
Market Impact: 0.12
Amneal Pharmaceuticals, Inc. Files Financials for Kashiv BioSciences Acquisition Involving $375.0 million Cash Consideration
Source: Nasdaq
M&A & RestructuringCompany Fundamentals
Amneal Pharmaceuticals filed an amendment to its Form 8-K providing historical financial statements for Kashiv BioSciences and pro forma financial information related to Amneal’s completed acquisition of Kashiv. The article provides no financial figures or other details about the acquisition’s terms or impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- +59%, +42%, +22%: Our AI just called these healthcare winners
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Systems for Hedge Funds: A Pilot Design
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations